Triple Agonist vs Single Agonist: A New Era
The comparison between retatrutide (triple agonist: GLP-1/GIP/glucagon) and Ozempic (semaglutide, single GLP-1 agonist) represents the evolution of incretin-based metabolic research from single-target to multi-target approaches. This guide examines the scientific differences.
What is Ozempic?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist approved for clinical use. It represents the current standard in single-receptor GLP-1 research.
Key Differences
| Feature | Retatrutide | Ozempic (Semaglutide) |
|---|---|---|
| Receptors | GLP-1 + GIP + Glucagon | GLP-1 only |
| Agonist type | Triple | Single |
| Development stage | Phase 2 completed | FDA approved |
| Dose range | 0.5-12mg weekly | 0.25-2.4mg weekly |
| GI side effects | Similar (dose-dependent) | Well-characterized |
The Glucagon Advantage
Retatrutide’s unique feature is glucagon receptor activation, which semaglutide lacks entirely. Glucagon increases hepatic fat oxidation, promotes thermogenesis, and enhances energy expenditure — mechanisms that complement the appetite-suppressing effects of GLP-1.
The GIP Component
The GIP receptor adds fat tissue-specific effects including enhanced lipid uptake and metabolism. This is the same mechanism that gives tirzepatide advantages over semaglutide alone.
Research Implications
Retatrutide’s phase 2 data showed the most impressive metabolic results of any incretin-based compound to date, suggesting that multi-receptor targeting may be the future of metabolic peptide research. However, semaglutide’s extensive clinical data and FDA approval provide a more comprehensive safety database.
For dosing details, see Retatrutide dosage guide and Semaglutide dosage chart.
For research purposes only. Visit COAs and catalog.
Related Articles
All products are sold strictly for research purposes only. Not for human consumption.